【摘要】 目的 :评价奥曲肽 (善宁 ,Sandostatin)对急性水肿性胰腺炎 (AEP)的治疗价值及应用指征 .方法 :将 15 2例AEP按年龄及有否加用奥曲肽分为 4组 .按下列指标评估 :腹痛消失时间、血淀粉酶复常时间、转为急性重症胰腺炎 (ANP)发生率、手术率、病死率 .结果 :大于 5 5岁的两组 ,腹痛消失时间奥曲肽治疗组 (治疗组 )为 (2 6± 1 5 )天 ,对照组为 (4 7± 2 3)天 ,p <0 0 5 ;血淀粉酶复常时间治疗组为 (3 1± 1 6 )天 ;对照组为 (4 6± 2 3)天 ,P <0 0 5 ;转为ANP的发生率 ,治疗组为 6 3% (2 /32 ) ,对照组为 2 5 6 % (10 /39) ,p <0 0 5 ;转手术率治疗组为 3 1% (1/32 ) ,对照组为10 3% (4/39) ,p >0 0 5 .小于或等于 5 5岁的两组 ,腹痛消失时间和血淀粉酶复常时间均无统计学差别 .结论 :AEP高龄患者早期应用奥曲肽治疗 ,能缩短病程 ,改善预后 ,减少ANP的发生更多还原

【Abstract】 Objective: To assess the value and indications of Octreotide in the treatment of acute edematous pancreatitis (AEP) methods: Abdominal pain duration; raised serum amylase period ; surgical intervention rate, mortality rate and occurrence race of acute necrosis pancreatitis (ANP) were investigated in 68 cases with AEP Results : in the old patients whose ages>55, abdominal pain duration was (2 6±1 5)days in treatment group with Octreotide and (4 7 ±2 3)days in control group respectively (p<0 05) Raised serum amylase period was (3 1± 1 6 ) days in treatment group with Octreotide and ( 4 6±2 7)days period in control group respectively (p<0 05) Occurrence rate of ANP was 6 3%(2 out of 32 cases) in treatment group with Octreotide while 25 6% ( 10 out of 39 ) in control group (p<0 05) in the young patients (ages≤55), significant differences were found in both treatment group with Octreotide and control group Conclusion: Octreotide in the old patients with AEP can shorten the course of the disease and improve prognosis更多还原